Vor Biopharma VOR Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Liquidity | ||||||
| Current ratio | 31.1×+27.3× | 18.2×+13.0× | 9.2×+4.5× | 3.5×-3.1× | 3.9×-4.6× | |
| Quick ratio | 31.1×+27.3× | 18.2×+13.0× | 9.2×+4.5× | 3.5×-3.1× | 3.9×-4.6× | |
| Cash ratio | 10.6×+7.6× | 15.8×+11.3× | 8.5×+4.8× | 3.2×-2.3× | 3×-0.4× | |
| Per Share | ||||||
| Book value per share | -$3.50-133% | -$16.64+40.8% | -$333.07-1,663% | -$12.02-937% | $10.59+485% | |
| Valuation | ||||||
| Market capitalization | $784.61M+2,594% | $286.59M+107% | $333.92M+598% | $39.75M-41.6% | $89.58M-44.3% | |
| Free cash flow yield | -18.6%+316pp | -50.1%+22.1pp | -43.3%+166pp | -287%-133pp | -112.3%-45.4pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Vor Biopharma's ratios come from?
- Every ratio is computed from Vor Biopharma's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.